Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
$0.17
$0.17
$0.11
$0.35
$12.89M1.133.16 million shs2.95 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$0.58
+0.1%
$0.57
$0.34
$2.55
$50.04M1.78580,755 shs639,676 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$2.18
-5.6%
$1.82
$0.87
$8.70
$73.18M0.25862,995 shs860,975 shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.76
-0.8%
$0.82
$0.52
$5.17
$64.19M1.641.12 million shs205,689 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
0.00%0.00%0.00%0.00%0.00%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
0.00%-3.25%-0.95%+6.82%-80.64%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%+5.31%+29.76%+50.34%-75.64%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
0.00%-0.20%-4.26%+43.94%-81.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/AN/AN/AN/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.2933 of 5 stars
3.55.00.00.02.41.70.6
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.8995 of 5 stars
3.44.00.00.00.60.00.6
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4.1524 of 5 stars
3.15.00.04.72.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
0.00
N/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.00
Buy$4.20623.14% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.80
Moderate Buy$9.60340.37% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.25
Hold$6.11704.51% Upside

Current Analyst Ratings Breakdown

Latest GNMX, OTLK, STRO, and IPSC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$2.00
6/6/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $21.00
5/20/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/19/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.80
5/16/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/AN/AN/AN/A$0.12 per shareN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$6.59M7.59N/AN/A$1.90 per share0.31
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($3.09) per shareN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$62.04M1.03N/AN/A$0.54 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
-$30.77M-$0.50N/AN/AN/A-898.31%-286.73%N/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%8/13/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)

Latest GNMX, OTLK, STRO, and IPSC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.38N/AN/AN/AN/AN/A
8/13/2025Q3 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.42N/AN/AN/A$1.66 millionN/A
8/12/2025Q2 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.53N/AN/AN/A$14.55 millionN/A
5/15/2025Q1 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million
5/15/2025Q2 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/A
0.65
0.65
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
11.70
11.70
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.72
0.57
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
2.16
2.16

Institutional Ownership

CompanyInstitutional Ownership
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
7.03%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%

Insider Ownership

CompanyInsider Ownership
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
43.80%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
5.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
1477.71 millionN/AOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
17086.16 million81.85 millionOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2033.57 million31.96 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.46 million81.42 millionOptionable

Recent News About These Companies

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Sutro Biopharma presents expanded data from REFRalphaME-01 trial
Wedbush Downgrades Sutro Biopharma (STRO)
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aevi Genomic Medicine stock logo

Aevi Genomic Medicine NASDAQ:GNMX

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$0.58 +0.00 (+0.10%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.59 +0.01 (+2.10%)
As of 07/18/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$2.18 -0.13 (-5.63%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.22 +0.04 (+2.06%)
As of 07/18/2025 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.76 -0.01 (-0.77%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.77 +0.01 (+1.18%)
As of 07/18/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.